See more : Schobrunn Paris SA (MLSCH.PA) Income Statement Analysis – Financial Results
Complete financial analysis of TriplePoint Venture Growth BDC Corp. (TPVG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TriplePoint Venture Growth BDC Corp., a leading company in the Asset Management industry within the Financial Services sector.
- Aether Catalyst Solutions, Inc. (ATHR.CN) Income Statement Analysis – Financial Results
- Jiangsu Sidike New Materials Science & Technology Co., Ltd. (300806.SZ) Income Statement Analysis – Financial Results
- SINBON Electronics Co., Ltd. (3023.TW) Income Statement Analysis – Financial Results
- Stran & Company, Inc. (STRNW) Income Statement Analysis – Financial Results
- Dragoneer Growth Opportunities Corp. (DGNR) Income Statement Analysis – Financial Results
TriplePoint Venture Growth BDC Corp. (TPVG)
About TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp. is a business development company specializing investments in venture capital-backed companies at the growth stage investments. It also provides debt financing to venture growth space companies which includes growth capital loans, secured and customized loans, equipment financings, revolving loans and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company's total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It targeted returns between 10% and 18%. It does not take board seat in the company.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 61.73M | 119.42M | 83.37M | 42.00M | 40.20M | 41.53M | 24.64M | 15.59M | 22.54M | 29.94M |
Cost of Revenue | -75.76M | 24.66M | 24.79M | 23.26M | 18.47M | 15.62M | 13.29M | 9.85M | 11.01M | 0.00 |
Gross Profit | 137.49M | 94.76M | 58.58M | 18.74M | 21.73M | 25.91M | 11.35M | 5.74M | 11.53M | 29.94M |
Gross Profit Ratio | 222.74% | 79.35% | 70.26% | 44.62% | 54.05% | 62.40% | 46.08% | 36.81% | 51.15% | 100.00% |
Research & Development | 0.00 | -0.27 | 1.14 | 0.35 | 0.44 | 0.55 | 0.37 | 0.49 | 0.00 | 0.00 |
General & Administrative | 9.00M | 6.70M | 6.13M | 6.70M | 6.04M | 4.96M | 4.30M | 4.47M | 4.35M | 10.37M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 9.00M | 6.70M | 6.13M | 6.70M | 6.04M | 4.96M | 4.30M | 4.47M | 4.35M | 10.37M |
Other Expenses | -36.07M | 51.42M | 681.00K | 38.76M | 2.40M | 2.55M | 3.63M | 2.58M | 2.67M | 0.00 |
Operating Expenses | -27.07M | 6.70M | 6.81M | 6.70M | 8.44M | 4.96M | 5.41M | 4.47M | 7.02M | 8.12M |
Cost & Expenses | -27.07M | 55.87M | 6.81M | 6.70M | 8.44M | 18.54M | 16.18M | 12.77M | 14.14M | 8.12M |
Interest Income | 133.25M | 116.57M | 82.83M | 88.57M | 70.52M | 62.61M | 50.04M | 41.77M | 39.90M | 4.68M |
Interest Expense | 33.04M | 26.76M | 17.37M | 15.49M | 10.01M | 9.08M | 9.06M | 7.86M | 3.62M | 0.00 |
Depreciation & Amortization | 0.00 | 66.73M | -27.22M | 48.93M | 28.60M | 29.75M | 31.01M | 11.79M | -2.82M | -20.05M |
EBITDA | 0.00 | 0.00 | 0.00 | -12.55M | -6.50M | 45.64M | 28.29M | 18.99M | 19.14M | -5.76M |
EBITDA Ratio | 0.00% | 68.61% | 91.83% | 84.06% | 79.00% | 103.78% | 104.60% | 105.25% | 84.92% | -9.67% |
Operating Income | 73.81M | 90.32M | 76.56M | 35.31M | 31.76M | 34.99M | 26.27M | 23.01M | 21.96M | 20.05M |
Operating Income Ratio | 119.57% | 75.63% | 91.83% | 84.06% | 79.00% | 84.26% | 106.60% | 147.59% | 97.43% | 66.95% |
Total Other Income/Expenses | -113.63M | -62.13M | -3.06M | 23.26M | -14.09M | 1.57M | -7.04M | -11.89M | 0.00 | -5.28M |
Income Before Tax | -39.82M | -20.07M | 76.56M | 35.31M | 31.76M | 36.56M | 19.23M | 11.13M | 15.52M | 17.15M |
Income Before Tax Ratio | -64.51% | -16.81% | 91.83% | 84.06% | 79.00% | 88.05% | 78.03% | 71.36% | 68.87% | 57.28% |
Income Tax Expense | 0.00 | 26.76M | 40.42M | 47.85M | 38.25M | 7.95M | 29.40M | 18.99M | 296.00K | -2.90M |
Net Income | -39.82M | -46.83M | 76.56M | 35.31M | 31.76M | 36.56M | 19.23M | 11.13M | 15.52M | 17.15M |
Net Income Ratio | -64.51% | -39.21% | 91.83% | 84.06% | 79.00% | 88.05% | 78.03% | 71.36% | 68.87% | 57.28% |
EPS | -1.12 | -1.43 | 2.47 | 1.16 | 1.28 | 1.78 | 1.18 | 0.69 | 1.03 | 1.74 |
EPS Diluted | -1.12 | -1.43 | 2.47 | 1.16 | 1.28 | 1.78 | 1.18 | 0.69 | 1.03 | 1.74 |
Weighted Avg Shares Out | 35.71M | 32.69M | 30.94M | 30.57M | 24.84M | 20.49M | 16.32M | 16.16M | 15.04M | 9.87M |
Weighted Avg Shares Out (Dil) | 35.71M | 32.69M | 30.94M | 30.57M | 24.84M | 20.49M | 16.32M | 16.16M | 15.04M | 9.87M |
Blood In The Streets? I'm Collecting 15% On My Capital: TriplePoint Venture Growth
TriplePoint Venture Growth: I'm Skipping The 15.2% Dividend Yield In 2024
BDCs Vs. MREITs: High-Yield Rumble
How To Invest $1,000 Per Month (November Edition)
TriplePoint Venture Growth: Now My Third-Largest BDC Position
TriplePoint Venture Group: 16% Well-Covered Yield, Q3 Earnings Up, Undervalued, Buy Rating
Triplepoint Venture Growth BDC Corporation (TPVG) Q3 2023 Earnings Call Transcript
TriplePoint Venture Growth BDC Corp. Announces Third Quarter 2023 Financial Results
3 Dividend Stocks to Avoid at All Costs: October 2023
TriplePoint Venture Growth BDC Corp. to Announce 2023 Third Quarter Financial Results on Wednesday, November 1, 2023
Source: https://incomestatements.info
Category: Stock Reports